Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy

Wanjing Feng(Fudan University Shanghai Cancer Center), Xiaodong Zhu(Fudan University Shanghai Cancer Center), Weijian Guo, Jiliang Yin(Shanghai Medical College of Fudan University), Xin Liu(Shanghai University of Electric Power), Xiaoying Zhao(Handan College), Mingzhu Huang(Fudan University Shanghai Cancer Center), Zhiyu Chen(Chongqing University)
Oncology Letters
July 16, 2018
10.3892/ol.2018.9147
Cited by 3

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247